Business Context and Reporting Period
This Form 8-K filing by Abbott Laboratories reports corporate governance events occurring on October 8, 2004. The filing details the appointment of a new director and a corresponding amendment to the company's by-laws.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors amended the company's by-laws to increase the number of directors from thirteen to fourteen.
- New Director Appointment: William M. Daley, chairman of the Midwest for JPMorgan Chase & Co., was named to the Abbott Board of Directors effective immediately.
- Committee Assignments: The Board has not yet determined which committees Mr. Daley will join.
Outlook, Risks, and Contingencies
The filing notes a commercial relationship where JPMorgan Chase & Co. has provided commercial banking services to Abbott during 2004. No specific financial guidance, risk factors, or unusual items are disclosed in this document.
Investor Verification Checklist
- Verify the official press release (Exhibit 99.1) for details on Mr. Daley's background and potential conflicts of interest.
- Review the amended By-Laws (Exhibit 3.1) to confirm the new board size and any other governance changes.
- Monitor future filings for the assignment of Mr. Daley to specific board committees.